P. Staehr

发表

Tissue classification by texture and spectral analysis of intracoronary ultrasound radio-frequency data

S. Krass, H. Darius, H. Rupprecht, 1995, Computers in Cardiology 1995.

Reduction of Free Fatty Acids, Safety, and Pharmacokinetics of Oral GS‐9667, an A1 Adenosine Receptor Partial Agonist

L. Belardinelli, A. Dhalla, P. Staehr, 2013, Journal of clinical pharmacology.

Assessment of image quality of intracoronary ultrasound systems with tissue-equivalent vessel phantoms

S. Krass, H. Rupprecht, J. Meyer, 1994, Computers in Cardiology 1994.

Effects of Age, Gender, Obesity, and Diabetes on the Efﬁcacy and Safety of the Selective A 2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion Imaging Integrated

M. Cerqueira, A. Iskandrian, P. Nguyen, 2016 .

Drug-related problems in general practice: results from a development project in Denmark

J. Kjellberg, P. Staehr, H. Herborg, 2006, Pharmacy World and Science.

Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation.

P. Serruys, D. Dudek, Y. Onuma, 2017, JACC. Cardiovascular interventions.

Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging

M. Cerqueira, S. Underwood, E. Reyes, 2011, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy.

G. Stone, S. Ellis, D. Kereiakes, 2015, Journal of the American College of Cardiology.

Pharmacokinetics and Pharmacodynamic, Pharmacokinetic, Pharmacodynamic, and Electrocardiographic Effects of Dapoxetine and Moxifloxacin Compared With Placebo in Healthy Adult Male Subjects

Suneel K. Gupta, P. Staehr, N. Modi, 2009, Journal of clinical pharmacology.

Pharmacokinetics of Dapoxetine, a New Treatment for Premature Ejaculation: Impact of Age and Effects of a High‐Fat Meal

J. Mulhall, P. Staehr, N. Modi, 2006, Journal of clinical pharmacology.

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

P. Serruys, A. Íñiguez, H. Garcia-Garcia, 2015, The Lancet.

Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

M. Cerqueira, S. Underwood, A. Iskandrian, 2008, JACC. Cardiovascular imaging.

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.

W. Cheong, P. Serruys, G. Stone, 2015, European heart journal.

PAH Therapy In HIV: Lack Of Drug-Drug Interaction Between Ambrisentan And Ritonavir

P. Staehr, H. Gillies, J. Zack, 2011, ATS 2011.

The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stent.

W. Cheong, P. Serruys, R. D. de Winter, 2016, European heart journal. Quality of care & clinical outcomes.

On the biological half‐life of amitriptyline

P. Staehr, A. JØrgensen, 1976, The Journal of pharmacy and pharmacology.

TCT-613 ABSORB FIRST: An interim report on baseline characteristics and acute performance on the first 1,200 patients from a prospective, multi-center, global registry

W. Cheong, A. Seth, É. Eeckhout, 2014 .

Bioresorbable Vascular ScaffoldsTCT-513 ABSORB III PK: Pharmacokinetics of Everolimus Eluted from the Absorb Bioresorbable Vascular Scaffold (BVS)

G. Stone, S. Ellis, D. Kereiakes, 2015 .

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.

W. Cheong, P. Serruys, G. Stone, 2015, European heart journal.

Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging

E. Reyes, D. Zeng, B. Blackburn, 2011, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.